Heptares Therapeutics and Imperial College London agreed on a multiyear research and development deal focused on gastrointestinal disease. Under the collaboration, Heptares will fund and support the studies of work up to commercialization of any product resulting from the deal.
Heptares to advance gastrointestinal disease study with Imperial College London
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.